Fast Facts: Sugar-Sweetened Beverage Consumption - Centers for Disease Control and Prevention | CDC (.gov)

Overview of real-world treatment patterns and clinical outcomes with [¹⁷⁷Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer treated within the French Early-Access Program. The figure summarizes patient population, treatment exposure, efficacy outcomes and safety findings from routine clinical practice. Credit: KPL, Paris. Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy is safe and effective for patients with metastatic castration-resistant prostate cancer (mCRPC) in routine clinical practice, consistent with outcomes from the VISION trial. An analysis of outcomes from a French early-access program, the largest real-world cohort of patients studied to date, confirms the benefit-risk profile of the therapy, while also shedding light on patient selection and use trends. This research was published in The Journal of Nuclear Medicine.

Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC. In this video, Kim Chi, MD, FRCP, discusses the rationale and design of the phase 3 KLK2-comPAS trial (NCT07164443) evaluating pasritamig, alone and in combination with JNJ-9401, in patients with metastatic castration-resistant prostate cancer (mCRPC) who have exhausted available life-prolonging treatment options. The design of the study was presented at the 2026 European Society for Medical Oncology Annual Congress in Madrid, Spain as a trials in progress poster. Chi is a medical oncologist at BC Cancer in Vancouver, Canada, and a professor of medicine at the University of British Columbia. According to Chi, the KLK2-comPAS trial builds on the potential of kallikrein-related peptidase 2 (KLK2) as a therapeutic target because of its expression in normal and malignant prostate tissue. Pasritamig is a bispecific antibody that engages CD3 on T cells and KLK2 on prostate cancer cells to stimulate a targeted immune response.

Informations complètes et à jour, compilées par Google Actualités à partir de sources d'actualité du monde entier